skip to Main Content
Get your free newsletter: Actionable insight each morning for self-directed investors. 

UK drug development company ValiRx (AIM:VAL) has been in the headlines probably more than it would have liked since the beginning of November, when a trading update triggered a series of selloffs and a sharp decline in price.

The reaction, or possibly overreaction, has mostly removed the froth whipped up earlier this autumn after two private investors increased their holdings – one dutifully following it up on Twitter.

 

The rest of this article is not available as it is for members only. Please log in below or visit the registration page for Armchair Trader+ to see the benefits of becoming a member.


Log In or Sign Up to Continue Reading

Already an Armchair Trader+ member? Log in here:


Not a member yet? Sign up for your free trial or check out the benefits of membership.

Further content of this article is not available as it is for members only. Please visit the registration page for Armchair Trader+ for further details on the benefits of becoming a member.

Become a better investor with SharePad Designed to give you the confidence to pick your own investments, Sharepad gives you access to a wealth of information on UK, US & European stocks. Find out more

Please note this article does not constitute investment advice. Investors are encouraged to do their own research beforehand or consult a professional advisor.

Vanya Dragomanovic

Vanya Dragomanovich

Vanya is an award-winning financial journalist who has worked in both television and newswires. She spent over 10 years at Dow Jones covering commodity markets, including metals, coffee, cocoa and oil. She also reported from the floor of the London Metals Exchange, and appeared on CNBC to discuss international metals markets. Since then she has written for several leading financial publications, including serving as commodities editor for FTSE Global Markets.

Vanya continues to cover international commodities markets globally, specialising in particular on metals and alternative energy. She is also the author of a book on CFD trading.

Stocks in Focus

Here are some of the smaller companies we are following most closely. They all represent significant growth stories in our view. Our in-depth reports go into more detail on why we like them.

Comments


Get your free daily newsletter: 

Thanks to our Partners

Our partners are established, regulated businesses and we are grateful for their support.

Pepperstone
FP Markets
IG
Spreadex
Trade Nation
WisdomTree
ActivTrades
Back To Top